特瑞普利单抗联合新辅助化疗、胸腹腔镜食管癌根治术治疗食管鳞状细胞癌的临床效果观察  

Observation on Clinical Effect of Toripalimab Combined with Neoadjuvant Chemotherapy and Thoracic Laparoscopic Radical Resection of Esophageal Cancer in Treatment of Esophageal Squamous Cell Carcinoma

作　　者：徐赐淼 Xu Cimiao(Sihong County Fenjinting Hospital,Suqian 223900,Jiangsu Province,China)

机构地区：[1]泗洪县分金亭医院肿瘤科,江苏宿迁223900

出　　处：《中国社区医师》2025年第2期54-56,共3页Chinese Community Doctors

摘　　要：目的:探究特瑞普利单抗联合新辅助化疗、胸腹腔镜食管癌根治术治疗食管鳞状细胞癌的临床效果。方法:筛选2019年1月—2022年12月于泗洪县分金亭医院确诊为食管鳞状细胞癌患者86例作为观察对象,以随机数字表法分为两组,每组43例。两组均实施胸腹腔镜食管癌根治术治疗,对照组术前应用新辅助化疗,观察组在对照组基础上应用特瑞普利单抗。比较两组外周血淋巴细胞程序性死亡受体-1(PD-1)mRNA、程序性死亡配体-1(PD-L1)mRNA表达情况以及临床疗效。结果:治疗前,两组PD-1 mRNA、PD-L1 mRNA水平比较,无明显差异(P>0.05);治疗后,两组PD-1 mRNA、PD-L1 mRNA水平下降,观察组低于对照组(P<0.05)。观察组客观缓解率、临床获益率高于对照组(P<0.05)。结论:特瑞普利单抗联合新辅助化疗、胸腹腔镜食管癌根治术治疗食管鳞状细胞癌的临床效果显著,可明显调控PD-1/PD-L1水平,提高临床获益率。Objective:To explore the clinical effect of toripalimab combined with neoadjuvant chemotherapy and thoracic laparoscopic radical resection of esophageal cancer in treatment of esophageal squamous cell carcinoma.Methods:A total of 86 patients with esophageal squamous cell carcinoma diagnosed in Sihong County Fenjinting Hospital from January 2019 to December 2022 were screened as observation objects.They were divided into two groups with 43 cases in each group by random number table method.Both groups were treated with thoracic laparoscopic radical resection of esophageal cancer.The control group was treated with neoadjuvant chemotherapy before operation,and the observation group was treated with toripalimab on the basis of the control group.The peripheral blood lymphocyte programmed death receptor-1(PD-1)mRNA and programmed death ligand-1(PD-L1)mRNA expressions and clinical efficacy were compared between the two groups.Results:Before treatment,there was no significant difference in the PD-1 mRNA and PD-L1 mRNA levels between the two groups(P>0.05).After treatment,the PD-1 mRNA and PD-L1 mRNA levels in two groups decreased,and the levels were lower in the observation group than in the control group(P<0.05).The objective response rate and clinical benefit rate in the observation group were higher than those in the control group(P<0.05).Conclusion:Toripalimab combined with neoadjuvant chemotherapy and thoracic laparoscopic radical resection of esophageal cancer in the treatment of esophageal squamous cell carcinoma has significant clinical effects,and can significantly regulate the levels of PD-1/PD-L1 and increase the clinical benefit rate.

关 键 词：食管鳞状细胞癌 特瑞普利单抗 胸腹腔镜食管癌根治术 新辅助化疗 

分 类 号：R735.1[医药卫生—肿瘤]